Nocturnal, sleeping IOP keeps ophthalmologists up at night

Article

There is much to be learned about nocturnal-and, more importantly, sleeping-IOP if ophthalmologists are going to optimize glaucoma therapies, said Yaniv Barkana, MD, Department of Ophthalmology, Assaf Harofeh Medical Center, Israel.

There is much to be learned about nocturnal-and, more importantly, sleeping-IOP if ophthalmologists are going to optimize glaucoma therapies, said Yaniv Barkana, MD, Department of Ophthalmology, Assaf Harofeh Medical Center, Israel.

"What happens to IOP during the one-third of our lives that we're asleep? We know from several recent studies, and some not-so-recent, that supine, nighttime IOP is higher than daytime sitting IOP, in some cases on the order of 4 mm," Dr. Barkana said. "This may mean that glaucoma progression takes place while we are sleeping."

Unfortunately, Dr. Barkana said, there is not any single best way to measure IOP during sleep.

"Keep in mind that measuring nocturnal IOP is not the same as measuring sleeping IOP," he said. "We can measure IOP after waking patients, but even if we wake them gently, the change from sleeping to waking changes the equation."

Having an analysis of sleeping IOP could have implications for making a diagnosis of normal-tension glaucoma and increase the understanding of the mechanism of normal-tension glaucoma, according to Dr. Barkana. It may also alter treatment regimens.

"It may be that we choose to design and pursue therapies designed to blunt the sleeping IOP rise," he said.

Tools may become available for clinicians in the near future to help answer the question of what IOP is doing as we sleep, Dr. Barakana said. Implantable or contact lens-mounted monitors may allow for continuous IOP monitoring that may lead to new ways of thinking about glaucoma management.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.